UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  August 15, 2005

 

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-32501

 

33-0827593

(State or Other Jurisdiction of
Incorporation)

 

(Commission File
Number)

 

(I.R.S. Employer Identification
Number)

 

3020 Callan Road, San Diego, California  92121

(Address of principal executive offices, with zip code)

 

(858) 458-0900

(Registrant’s telephone number, including area code)

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 2.02                                             Results of Operations and Financial Conditions

 

A press release was issued by Cytori Therapeutics, Inc. on August 15, 2005, reporting financial results for the quarter and six months ended June 30, 2005.  A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01                                             Financial Statements and Exhibits

 

(c)                                  Exhibits

 

Exhibit 99.1                                  Press release issued by Cytori Therapeutics, Inc. on August 15, 2005, reported financial results for the quarter and six months ended June 30, 2005.

 

2



 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CYTORI THERAPEUTICS, INC.

 

 

 

 

Date:  August 15, 2005

By:

/s/

CHRISTOPHER J. CALHOUN

 

 

 

Christopher J. Calhoun

 

 

Chief Executive Officer

 

3



 

EXHIBIT INDEX

 

 

Exhibit Number

 

Description of Document

99.1

 

Press release issued by Cytori Therapeutics, Inc. on August 15, 2005, reported financial results for the quarter and six months ended June 30, 2005.

 

4


Exhibit 99.1

 

 

 

Contacts:

 

 

Tom Baker

 

Stefanie Bacher

Media/U.S. Investors

 

International Investors

Tel. +1-858-458-0900

 

Tel. +1-858-362-0365

tbaker@cytoritx.com

 

sbacher@cytoritx.com

 

Cytori Therapeutics Announces Second Quarter and Six Month Financial Results

 

San Diego, CA August 15, 2005 - Cytori Therapeutics, Inc. (Frankfurt: XMP), a biotechnology company innovating regenerative medicine, announced financial results for the quarter and six months ended June 30, 2005.

 

“In the second quarter of 2005, Cytori Therapeutics continued to advance its development of adipose stem cell therapies and systems,” said Christopher J. Calhoun, Chief Executive Officer of Cytori Therapeutics. “During the first half, three accomplished medical scientists joined the Company to bolster our research and clinical development and, after the end of the quarter, we published preclinical research findings demonstrating adipose stem cells may repair damage to an injured heart through multiple mechanisms. Additionally, in May, we received $11.0 million from a strategic equity agreement that we entered into with Olympus Corporation.”

 

Cytori Therapeutics strategically reorganized the company due to its shift in focus toward and progress in the development of cell-based treatments. This reorganization includes a new corporate name and the creation of a separate division for its surgical implants business. This division will operate under the name MacroPore Biosurgery and will report financial information as an operating segment of Cytori Therapeutics. 

 

For the remainder of 2005, Cytori Therapeutics expects to complete its first regenerative cell technology partnership, submit additional regulatory filings for the Celution™ system, which we recently completed development of, and report on additional results from multiple preclinical studies.

 

Financials

 

Total revenues for the second quarter of 2005 were $1,541,000 compared to $1,540,000 for the same period in 2004. Of the total revenue for the second quarter of 2005, $1,477,000 was attributable to HYDROSORB™ spine and orthopedic implant sales, compared to $886,000 for the same period in 2004. Total revenues for the first half of 2005 were $3,330,000 compared to $3,892,000 for the first half of 2004. Of the total revenue in the first half, $3,232,000 was attributable to HYDROSORB™ sales to Medtronic, compared to $2,533,000 for the same period in 2004. The increase in HYDROSORB™ revenues for the second quarter and first half of 2005 is due predominantly to stocking orders for the radiographically identifiable Spine System products, marketed under the name MYSTIQUE™, which was recently launched by Medtronic.

 

Net loss for the second quarter of 2005 was $5,359,000 compared to a net loss of $3,810,000 for the same period in 2004. Net loss for the first half of 2005 was $9,886,000 compared to a net loss of $2,320,000 for the same period in 2004. The net loss in the first half of 2004 included a $5,000,000 gain related to the sale of the Craniomaxillofacial product line to Medtronic. Net loss in the first half of 2004 before the gain was $7,320,000 as shown in the table below(1). The increase in net loss for the second quarter and first half of 2005 is primarily attributable to the increase in research and development related to the cell-based therapeutics and systems.

 

 

 

Six Months Ended June 30,

 

 

 

2005

 

2004

 

Net loss GAAP

 

$

(9,886,000

)

$

(2,320,000

)

Less: Gain on the sale of asset, related party

 

 

(5,000,000

)

Adjusted net loss

 

$

(9,886,000

)

$

(7,320,000

)

 


(1) The Company believes adjusted net loss is a useful measure by which investors can evaluate our operating performance on a comparable basis, unaffected by the $5,000,000 payment we recorded in the first half of 2004.

 



 

Cytori Therapeutics ended the second quarter of 2005 with $14,822,000 in cash, cash equivalents and short-term investments and $491,000 in accounts receivable.  

 

Conference Call Information

 

The management of Cytori Therapeutics will host a conference call today at 10:00 a.m. Eastern Daylight Time (EDT) or 4:00 p.m. Central European Summer Time (CEST). The conference call will be webcast live and may be accessed under “Events & Webcasts” in the Investor Relations section of the Company’s website at http://www.cytoritx.com. The archived version of the webcast will be available 60 minutes after the call on the company’s website and accessible for 90 days.  A telephone replay will be available for one week. To access the replay, please call +1 (303) 590-3000 (PIN: 11036406#) or +49 (0) 69- 58 99 90 568 (PIN: 133371#).

 

About Cytori Therapeutics

 

Cytori Therapeutics (Frankfurt: XMP) is discovering and developing proprietary cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The Company’s investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution™ system to isolate and concentrate a patient’s own stem cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics’ future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company’s actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading “Risk Factors”) in Cytori Therapeutics’ 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company’s web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.

 

###

 



 

CONSOLIDATED CONDENSED BALANCE SHEETS

 

 

 

As of June 30,
2005

 

As of December
31, 2004

 

 

 

(Unaudited)

 

 

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

3,076,000

 

$

2,840,000

 

Short-term investments, available-for-sale

 

11,746,000

 

10,579,000

 

Accounts receivable, net of allowance for doubtful accounts of $5,000 and $8,000 in 2005 and 2004, respectively

 

491,000

 

863,000

 

Inventories

 

532,000

 

379,000

 

Other current assets

 

901,000

 

984,000

 

 

 

 

 

 

 

Total current assets

 

16,746,000

 

15,645,000

 

 

 

 

 

 

 

Property and equipment, net

 

2,900,000

 

3,080,000

 

Other assets

 

393,000

 

236,000

 

Intangibles, net

 

1,987,000

 

2,122,000

 

Goodwill

 

4,387,000

 

4,387,000

 

 

 

 

 

 

 

Total assets

 

$

26,413,000

 

$

25,470,000

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable and accrued expenses

 

$

2,489,000

 

$

2,329,000

 

Current portion of long-term obligations

 

773,000

 

938,000

 

 

 

 

 

 

 

Total current liabilities

 

3,262,000

 

3,267,000

 

 

 

 

 

 

 

Deferred gain on sale of assets

 

5,650,000

 

5,650,000

 

Deferred license fee revenue

 

1,500,000

 

1,500,000

 

Deferred development revenue

 

1,083,000

 

1,092,000

 

Option liability

 

246,000

 

 

Deferred other

 

7,811,000

 

 

Long-term obligations, less current portion

 

819,000

 

1,128,000

 

 

 

 

 

 

 

Total liabilities

 

20,371,000

 

12,637,000

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2005 and 2004

 

 

 

Common stock, $0.001 par value; 95,000,000 shares authorized; 18,040,018 and 16,820,018 shares issued and 15,167,184 and 13,947,184 shares outstanding in 2005 and 2004, respectively

 

18,000

 

17,000

 

Additional paid-in capital

 

77,817,000

 

74,737,000

 

Accumulated deficit

 

(61,361,000

)

(51,475,000

)

Treasury stock, at cost

 

(10,414,000

)

(10,414,000

)

Accumulated other comprehensive loss

 

(18,000

)

(32,000

)

 

 

 

 

 

 

Total stockholders’ equity

 

6,042,000

 

12,833,000

 

 

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

26,413,000

 

$

25,470,000

 

 



 

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

 

 

For the Three Months
Ended June 30,

 

For the Six Months
Ended June 30,

 

 

 

2005

 

2004

 

2005

 

2004

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

Sales to related party

 

$

1,477,000

 

$

894,000

 

$

3,232,000

 

$

2,815,000

 

Sales to third parties

 

2,000

 

636,000

 

4,000

 

977,000

 

Research grant

 

62,000

 

10,000

 

85,000

 

100,000

 

Development

 

 

 

9,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,541,000

 

1,540,000

 

3,330,000

 

3,892,000

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

Cost of revenues including stock based compensation expense of $0 and $1,000 for the three months ended June 30, 2005 and 2004 respectively; $0 and $3,000 for the six months ended June 30, 2005 and 2004, respectively

 

738,000

 

314,000

 

1,483,000

 

1,191,000

 

Inventory provision

 

 

 

 

242,000

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

803,000

 

1,226,000

 

1,847,000

 

2,459,000

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development, excluding stock based compensation expense of $63,000 and $32,000 for the three months ended June 30, 2005 and 2004, respectively; $63,000 and $32,000 for the six months ended June 30, 2005 and 2004, respectively

 

3,596,000

 

2,668,000

 

6,869,000

 

5,175,000

 

Sales and marketing, excluding stock based compensation expense of $0 and $11,000 for the three months ended June 30, 2005 and 2004, respectively; $0 and $22,000 for the six months ended June 30, 2005 and 2004, respectively

 

337,000

 

654,000

 

728,000

 

1,612,000

 

General and administrative, excluding stock based compensation expense of $0 and $36,000 for the three months ended June 30, 2005 and 2004, respectively; $0 and $71,000 for the six months ended June 30, 2005 and 2004, respectively

 

2,098,000

 

1,575,000

 

4,007,000

 

2,801,000

 

Stock based compensation (excluding cost of revenues stock based compensation)

 

63,000

 

79,000

 

63,000

 

125,000

 

Change in fair value of option liability

 

60,000

 

 

60,000

 

 

Restructuring charge

 

 

70,000

 

 

70,000

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

6,154,000

 

5,046,000

 

11,727,000

 

9,783,000

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

(5,351,000

)

(3,820,000

)

(9,880,000

)

(7,324,000

)

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

Gain on sale of assets, related party

 

 

 

 

5,000,000

 

Interest income

 

54,000

 

57,000

 

109,000

 

112,000

 

Interest expense

 

(36,000

)

(48,000

)

(76,000

)

(87,000

)

Other income (expense), net

 

(26,000

)

1,000

 

(39,000

)

(21,000

)

Total other income (expense)

 

(8,000

)

10,000

 

(6,000

)

5,004,000

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(5,359,000

)

(3,810,000

)

(9,886,000

)

(2,320,000

)

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss): unrealized holding income (loss)

 

14,000

 

(41,000

)

14,000

 

(50,000

)

 

 

 

 

 

 

 

 

 

 

Comprehensive loss

 

$

(5,345,000

)

$

(3,851,000

)

$

(9,872,000

)

$

(2,370,000

)

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$

(0.37

)

$

(0.27

)

$

(0.70

)

$

(0.17

)

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted average common shares

 

14,379,849

 

13,920,186

 

14,168,234

 

13,933,111

 

 



 

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

 

For the six months ended June 30,

 

 

 

2005

 

2004

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net loss

 

$

(9,886,000

)

(2,320,000

)

Adjustments to reconcile loss to net cash used in operating activities:

 

 

 

 

 

Depreciation and amortization

 

861,000

 

866,000

 

Inventory provision

 

 

242,000

 

Reduction in allowance for doubtful accounts

 

(3,000

)

(19,000

)

Change in fair value of option liability

 

60,000

 

 

Restructuring charge

 

 

70,000

 

Amortization of gain on sale of assets, related party

 

 

(156,000

)

Amortization of gain on sale of assets

 

 

(189,000

)

Gain on sale of assets, related party

 

 

(5,000,000

)

Stock based compensation

 

63,000

 

119,000

 

Increases (decreases) in cash caused by changes in operating assets and liabilities:

 

 

 

 

 

Accounts receivable

 

375,000

 

(147,000

)

Inventories

 

(153,000

)

(51,000

)

Other current assets

 

83,000

 

(79,000

)

Other assets

 

(157,000

)

35,000

 

Accounts payable and accrued expenses

 

160,000

 

(413,000

)

Deferred development revenue

 

(9,000

)

58,000

 

 

 

 

 

 

 

Net cash used in operating activities

 

(8,606,000

)

(6,984,000

)

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Proceeds from sale and maturity of short-term investments

 

22,089,000

 

30,006,000

 

Purchases of short-term investments

 

(23,242,000

)

(34,548,000

)

Proceeds from sale of assets, related party

 

 

5,000,000

 

Proceeds from sale of assets, net

 

 

6,960,000

 

Purchases of property and equipment

 

(546,000

)

(463,000

)

Acquisition costs

 

 

(21,000

)

 

 

 

 

 

 

Net cash (used in) provided by investing activities

 

(1,699,000

)

6,934,000

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Principal payments on long-term obligations

 

(474,000

)

(382,000

)

Proceeds from long-term obligations

 

 

722,000

 

Proceeds from exercise of employee stock options

 

15,000

 

26,000

 

Proceeds from sale of common stock

 

3,003,000

 

 

Proceeds from issuance of options

 

186,000

 

 

Proceeds received in excess of fair market value of common stock

 

7,811,000

 

 

Purchase of treasury stock

 

 

(1,043,000

)

 

 

 

 

 

 

Net cash provided by (used in) financing activities

 

10,541,000

 

(677,000

)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

236,000

 

(727,000

)

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

2,840,000

 

2,820,000

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

3,076,000

 

$

2,093,000